Topic: checkpoint inhibitors
Last week’s biotech discoveries include a gut-coating pill that lowers glucose and prostate-tumor test to predict a good response to immunotherapy.
BMS is combining Opdivo and cabiralizumab, an anti-CSF-1 antibody, with Apexigen’s lead CD40 activator in an early-phase solid tumor study.
Idera Pharmaceuticals' TLR antagonist, IMO-8400, failed to improve skin symptoms in adults with dermatomyositis.
Oncologie launched operations in Boston and Shanghai with a $16.5 million seed round, aiming to deliver drugs to China and the U.S. simultaneously.
X4 Pharma said the 23% objective response rate was "encouraging" as it was observed in third-line patients, a group whose response rate hovers around 10%.
Swiss oncology biotech Nouscom nabbed Pfizer’s former global clinical leader of early and late stage I-O/hematology Adrian Woolfson as its new CMO.
Eli Lilly is acquiring Armo Biosciences and its lead asset, a PEGylated form of the cytokine IL-10, for $1.6 billion.
The funding will advance its pipelines of synthetic cytokines, designed to improve immuno-oncology treatments.
FDA officials caused the delay by demanding to see additional CMC information before signing off on the study.
A combination of Checkmate's TLR9 agonist and Merck's Keytruda reversed PD-1 resistance in melanoma patients.